Manager TitleAgeSince
Investor Relations Contact 61 -
Director of Finance/CFO 68 2020-09-29
Change 5-day change 1-year change 3-year change Capi.($)
+1.44%+59.69% - - 53.5M
+0.68%+5.92%+80.45%+137.78% 59.1B
+2.32%+5.03%+75.51%+94.88% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+45.58%-1.42% 19.69B
-0.29%+9.78%+44.62%-27.94% 17.56B
0.00%+20.78%+178.93%+360.74% 16.22B
+3.50%+1.97%+21.02%+191.95% 14.04B
+6.72%+19.38%+42.82% - 14.84B
Average +2.73%+8.57%+54.64%+148.04% 27.28B
Weighted average by Cap. +2.46%+6.47%+59.06%+137.71%
Logo Tyme Technologies Inc
Tyme Technologies, Inc. is a biotechnology company. The Company is developing cancer metabolism-based therapies (CMBTs ) that are effective across a broad range of solid tumors and hematologic cancers. It is focused on developing its novel compound, SM-88 and its preclinical pipeline of novel CMBT programs. SM-88 is an oral investigational modified proprietary tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells? key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. Its therapeutic approach is designed to take advantage of a cancer cells innate metabolic weaknesses to cause cancer cell death.
Employees
-